Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Among these, Geron Corporation GERN and Crinetics Pharmaceuticals CRNX gained on positive regulatory and study updates, respectively. Recap of the Week's Most Important Stories Updates From Bristol Myers Bristol Myers BMY announced that the European Commission (EC) has approved a label expansion chimeric antigen receptor (CAR) T cell immunotherapy Abecma (idecabtagene vicleucel; ide-cel). The CAR T cell therapy is now approved in the European Union (EU) in earlier lines for triple-class exposed relapsed and refractory multiple myeloma. Abecma is already approved in the EU, Switzerland, Japan, the United Kingdom and Israel for adult patients with triple-class exposed relapsed or refractory multiple myeloma after three to four or more prior lines of therapy. Earlier, the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor (8:3) of Abecma's benefit/risk profile for patients with triple-class exposed relapsed and refractory multiple myeloma in earlier lines of therapy. The
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $54.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at JMP Securities from $60.00 to $80.00. They now have a "market outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Jonestrading from $52.00 to $56.00. They now have a "buy" rating on the stock.MarketBeat
CRNX
Earnings
- 2/28/24 - Miss
CRNX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- CRNX's page on the SEC website